Pfizer stock: Pfizer gains 2.30 percent versus Xetra close. Pfizer stock trades at EUR 26.72

Published on 10/20/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer's second-quarter revenue reached USD 15.03 billion. Pfizer stock costs EUR 26.72 on October 20, 2026, up 2.30 percent versus the Xetra close.

Pfizer gains 2.30 percent

Pfizer stock gained 2.30 percent against the Xetra close on October 20, 2026.
Second-quarter revenue reached USD 15.03 billion, while adjusted earnings per share were USD 0.77.
Pfizer stock costs EUR 26.72 at Lang & Schwarz on October 20, 2026 at 5:00 p.m. CEST, 2.30 percent above the Xetra close of October 19, 2026 and 0.63 percent below the NYSE high.
Pfizer is scheduled to report its next results on November 3, 2026.

Sanfte Aquarell-Illustration einer Bürotürme-Skyline, Symbolbild für Pfizer Inc. Hauptsitz — Aquarellmalerei der New Yorker Skyline repräsentiert den Firmensitz von Pfizer Inc., ISIN US7170811035, Pharma-Branche, Illustration mit AI erstellt.

Pfizer stock gained 2.30 percent against the Xetra close on October 20, 2026, making the euro quotation the day's clearest investor signal. The latest reported quarter brought USD 15.03 billion in revenue and adjusted diluted earnings per share of USD 0.77, according to Yahoo Finance. Pfizer stock was trading at EUR 26.72 at Lang & Schwarz on October 20, 2026 at 5:00 p.m. CEST, plus 2.30 percent versus the Xetra close of October 19, 2026 at EUR 26.12.

Revenue reached USD 15.03 billion

Pfizer's second-quarter revenue rose 1.00 percent on an operational basis from the prior-year quarter, while revenue excluding COVID products grew 5.00 percent operationally, according to Yahoo Finance. Adjusted diluted earnings per share reached USD 0.77 in the second quarter of 2026, compared with a GAAP loss per share of USD 0.04 after USD 4.30 billion in non-cash intangible asset impairments.

Pfizer stock sits below its yearly high

On the NYSE, Pfizer was last at USD 30.04 on October 20, 2026 at 11:02 a.m. EDT, while its 52-week range was USD 23.62 to USD 30.23. The USD 30.04 level stood 0.63 percent below the yearly high, keeping the primary-market quotation near its upper boundary while the euro price gained 2.30 percent against Xetra.

Valuation and the next report date

Pfizer had a market capitalization of USD 171.2 billion and a price-to-earnings ratio of 39.68 on October 20, 2026. Its next report is scheduled for November 3, 2026, according to 24/7 Wall St.

What does the quarter mean for Pfizer?

The numbers point to a split operating picture. Pfizer's non-COVID portfolio delivered the stronger contribution in the second quarter, but the reported loss and the impairment charge kept GAAP profitability negative. Management also raised the midpoint of full-year 2026 revenue guidance by USD 0.50 billion to a range of USD 60.50 billion to USD 62.50 billion, while maintaining adjusted diluted earnings-per-share guidance of USD 2.80 to USD 3.00, according to Yahoo Finance.

Price remains near the upper range

The primary-market price and euro quotation point to different reference currencies, so the NYSE range is best read separately from the Lang & Schwarz move. Pfizer stock was trading at EUR 26.72 at Lang & Schwarz on October 20, 2026 at 5:00 p.m. CEST, plus 2.30 percent versus the Xetra close of October 19, 2026 at EUR 26.12. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.